CoChat

International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes

Bergman, Michael, Manco, Melania, Satman, Ilhan, Chan, Juliana, Schmidt, Maria Inês, Sesti, Giorgio, Vanessa Fiorentino, Teresa, Abdul-Ghani, Muhammad, Jagannathan, Ram, Kumar Thyparambil Aravindakshan, Pramod, Gabriel, Rafael, Mohan, Viswanathan, Buysschaert, Martin, Bennakhi, Abdullah, Pascal Kengne, Andre, Dorcely, Brenda, Nilsson, Peter M., Tuomi, Tiinamaija, Battelino, Tadej, Hussain, Akhtar, Ceriello, Antonio, Tuomilehto, Jaakko · 2024 · Diabetes Research and Clinical Practice
Cited by 171

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Many individuals with intermediate hyperglycaemia (IH), including impaired fasting glycaemia (IFG) and impaired glucose tolerance (IGT), as presently defined, will progress to type 2 diabetes (T2D). There is confirmatory evidence that T2D can be prevented by lifestyle modification and/or medications, in people with IGT diagnosed by 2-h plasma glucose (PG) during a 75-gram oral glucose tolerance test (OGTT). Over the last 40 years, a wealth of epidemiological data has confirmed the superior value of 1-h plasma glucose (PG) over fasting PG (FPG), glycated haemoglobin (HbA1c) and 2-h PG in populations of different ethnicity, sex and age in predicting diabetes and associated complications including death. Given the relentlessly rising prevalence of diabetes, a more sensitive, practical method is needed to detect people with IH and T2D for early prevention or treatment in the often lengthy trajectory to T2D and its complications. The International Diabetes Federation (IDF) Position Statement reviews findings that the 1-h post-load PG ≥ 155 mg/dL (8.6 mmol/L) in people with normal glucose tolerance (NGT) during an OGTT is highly predictive for detecting progression to T2D, micro- and macrovascular complications, obstructive sleep apnoea, cystic fibrosis-related diabetes mellitus, metabolic dysfunction-associated steatotic liver disease, and mortality in individuals with risk factors. The 1-h PG of 209 mg/dL (11.6 mmol/L) is also diagnostic of T2D. Importantly, the 1-h PG cut points for diagnosing IH and T2D can be detected earlier than the recommended 2-h PG thresholds. Taken together, the 1-h PG provides an opportunity to avoid misclassification of glycaemic status if FPG or HbA1c alone are used. The 1-h PG also allows early detection of high-risk people for intervention to prevent progression to T2D which will benefit the sizeable and growing population of individuals at increased risk of T2D. Using a 1-h OGTT, subsequent to screening with a non-laboratory diabetes risk tool, and intervening early will favourably impact the global diabetes epidemic. Health services should consider developing a policy for screening for IH based on local human and technical resources. People with a 1-h PG ≥ 155 mg/dL (8.6 mmol/L) are considered to have IH and should be prescribed lifestyle intervention and referred to a diabetes prevention program. People with a 1-h PG ≥ 209 mg/dL (11.6 mmol/L) are considered to have T2D and should have a repeat test to confirm the diagnosis of T2D and then referred for further evaluation and treatment. The substantive data presented in the Position Statement provides strong evidence for redefining current diagnostic criteria for IH and T2D by adding the 1-h PG.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.diabres.2024.111589

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Metadata

Authors
Bergman, M., Manco, M., Satman, I., Chan, J., Schmidt, M. I., Sesti, G., Vanessa Fiorentino, T., Abdul-Ghani, M., Jagannathan, R., Kumar Thyparambil Aravindakshan, P., Gabriel, R., Mohan, V., Buysschaert, M., Bennakhi, A., Pascal Kengne, A., Dorcely, B., Nilsson, P. M., Tuomi, T., Battelino, T., Hussain, A., Ceriello, A., & Tuomilehto, J.
Venue
Diabetes Research and Clinical Practice
Publisher
Elsevier BV
Published
2024-03
Volume
209
Pages
111589
ISSN
0168-8227 (ISSN-L)
OpenAlex
W4392558086
Cited by
171
References
25
FWCI
46.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes. https://app.cochat.ai/papers/10.1016/j.diabres.2024.111589
The paper
Bergman, M., Manco, M., Satman, I., Chan, J., Schmidt, M. I., Sesti, G., Vanessa Fiorentino, T., Abdul-Ghani, M., Jagannathan, R., Kumar Thyparambil Aravindakshan, P., Gabriel, R., Mohan, V., Buysschaert, M., Bennakhi, A., Pascal Kengne, A., Dorcely, B., Nilsson, P. M., Tuomi, T., Battelino, T., . . . Tuomilehto, J. (2024). International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes. Diabetes Research and Clinical Practice. https://doi.org/10.1016/j.diabres.2024.111589

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.